SCHEMBL517089

SCHEMBL517089

Cn1ccc2ccc(S(N)(=O)=O)cc21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
LMNA P02545 1/20 0.47
ALDH1A1 P00352 1/20 0.45
CA1 P00915 9/20 0.44
CA2 P00918 6/20 0.44
CA9 Q16790 6/20 0.44
CA12 O43570 5/20 0.44
PIK3CG P48736 1/20 0.44
PRKCI P41743 1/20 0.42
PKM P14618 1/20 0.40
CA6 P23280 2/20 0.39
CA5A P35218 2/20 0.39
CA7 P43166 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA14 Q9ULX7 1/20 0.39
PIK3CB P42338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8761290 0.86 PRKCI (0.55) CYP2A6LMNAALDH1A1CA1CA2
SCHEMBL2177417 0.84 CYP2A6 (0.51) CYP2A6PRKCIPKM
SCHEMBL793097 0.82 CYP2A6 (0.50) CYP2A6ALDH1A1PRKCIPKMPIK3CB
SCHEMBL22951479 0.79 CYP2A6 (0.47) CYP2A6LMNAALDH1A1PRKCIPKM
SCHEMBL8187354 0.75 LMNA (0.43) LMNAALDH1A1CA1CA2CA9
SCHEMBL31647188 0.75 PKM (0.44) CYP2A6LMNAALDH1A1CA1CA2
SCHEMBL31743063 0.75 PIK3CG (0.48) LMNAALDH1A1CA1CA2CA9
SCHEMBL19259568 0.75 CA1 (0.51) CYP2A6ALDH1A1CA1CA2CA9
SCHEMBL28312591 0.74 CA1 (0.50) LMNAALDH1A1CA1CA2CA9
SCHEMBL517778 0.73 LMNA (0.50) LMNACA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110036004-A Inhibitors of cyclin dependent kinase 7(CDK7) 希洛斯医药品股份有限公司 2019-07-19 CN disclosed
US-9789118-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2017-10-17 US disclosed
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2014-06-19 US disclosed
US-8697739-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2014-04-15 US disclosed
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY CYP2A6 394/4885LMNA 2697/4885ALDH1A1 215/4885
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY CYP2A6 394/4885LMNA 2697/4885ALDH1A1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.